Diabetes

    Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis

    Tricco AC, Ashoor HM, Antony J, Beyene J, Veroniki AA, Isaranuwatchai W, Harrington A, Wilson C, Tsouros S, Soobiah C, Yu CH, Hutton B, Hoch JS, Hemmelgarn BR, Moher D, Majumdar SR, Straus SE. Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis. BMJ. 2014;349:g5459. DOI:10.1136/bmj.g5459.

    Altmetric:

    Impact:

    • Conducted for the British Columbia Ministry of Health to inform the decision to continue listing the insulin in the same manner
    • Featured in >220 mass media articles
    • Used to update the WHO Model Lists of Essential Medicines
    Funding:

    Canadian Institutes of Health Research (CIHR)/ Drug Safety and Effectiveness Network (DSEN)


    Safety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycaemic agents: a systematic review and network meta-analysis

    Tricco AC, Antony J, Khan PA, Ghassemi M, Hamid JS, Ashoor H, Blondal E, Soobiah C, Yu CH, Hutton B, Hemmelgarn BR, Moher D, Majumdar SR, Straus SE. Safety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycaemic agents: a systematic review and network meta-analysis. BMJ Open. 2014;4(12):e005752. DOI: 10.1136/bmjopen-2014-005752.

    Altmetric:

    Impact:

    • Conducted for the British Columbia Ministry of Health to inform the decision to delist DPP-4 inhibitors for T2DM patients in British Columbia
    Funding:

    Canadian Institutes of Health Research (CIHR)/ Drug Safety and Effectiveness Network (DSEN)

     

    Category :

    Date : 22 Mar 2016